Moderna MRNA incurred a loss of $2.50 per share in the fourth quarter of 2024, narrower than the Zacks Consensus Estimate of ...

MRNA's competitive landscape, particularly against Pfizer, and higher forward P/S ratio suggest the stock is overvalued and ...

The biopharma reported disappointing fourth-quarter results, missing bottom line estimates amid a steep decline in COVID-19 ...

Yahoo Finance host Julie Hyman is tracking this morning's trending stock tickers in this Market Minute: SoundHound AI (SOUN), ...

Moderna’s consensus price target has significantly declined from $119.26 to $47.5, indicating a cautious outlook from ...

Moderna (MRNA) came out with a quarterly loss of $2.50 per share versus the Zacks Consensus Estimate of a loss of $2.69. This compares to earnings of $0.55 per share a year ago. These figures are ...

After its depression candidate failed a phase 3 trial and disappointed analysts, Neumora is shaking up its leadership team.

Reports fourth quarter revenues of $1.0 billion, GAAP net loss of $(1.1) billion and GAAP EPS of $(2.91); loss includes approximately $0.2 billion of non-cash charges related to manufacturing resizing ...

Reports fourth quarter revenues of $1.0 billion, GAAP net loss of $(1.1) billion and GAAP EPS of $(2.91); loss includes approximately $0.2 billion of non-cash charges related to manufacturing resizing ...

Moderna (MRNA) expects revenue of approximately $0.2B in the first half of the year, reflecting the seasonality of its respiratory business.

Biotechnology company Moderna (NASDAQ:MRNA) met Wall Street’s revenue expectations in Q4 CY2024, but sales fell by 65.6% year ...

Reports Q4 revenue $966M, consensus $941.14M. The company reported $923M in Spikevax sales in the fourth quarter of 2024 and $15M in mRESVIA ...